TY - JOUR
T1 - Barriers and facilitators for systematically registering adverse drug reactions in electronic health records
T2 - a qualitative study with Dutch healthcare professionals
AU - Geeven, Isa P. A. C.
AU - Jessurun, Naomi T.
AU - Wasylewicz, Arthur T. M.
AU - Drent, Marjolein
AU - Spuls, Phyllis I.
AU - Hoentjen, Frank
AU - van Puijenbroek, Eugène P.
AU - Vonkeman, Harald E.
AU - Grootens, Koen P.
AU - van Doorn, Martijn B. A.
AU - van den Bemt, Bart J. F.
AU - Bekkers, Charlotte L.
AU - Bekker, Charlotte L.
N1 - Funding Information: This paper was not funded. Publisher Copyright: © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - Background: Systematically registering ADRs in electronic health records (EHRs) likely contribute to patient safety as it enables the exchange of drug safety data. Currently, ADRs registrations by healthcare professionals (HCPs) is suboptimal. This study aimed to identify barriers and facilitators perceived by HCPs to register ADRs systematically in EHRs. Research Design and Methods: A qualitative study with individual interviews was conducted among specialist physicians and hospital pharmacists from 10 different Dutch hospitals. A semi-structured interview guide was used to identify experienced barriers and facilitators for systematically registering ADRs. Data was analyzed following thematic analysis. Themes within barriers and facilitators were aligned with the Capability–Opportunity-Motivation–Behavior (COM-B) framework. Results: In total, 16 HCPs were interviewed. Identified barriers were: lack of knowledge to recognize ADRs, time constraints, inadequate IT system, lack of support, stuck in routine, and not recognizing the importance of registering ADRs. Identified facilitators were: enhanced knowledge and awareness of ADRs, functional IT systems, expanding accountability for registration, and motivation toward registering. Conclusions: Barriers and facilitators for registering spanned all aspects of the COM-B model and occurred in individual, social and environmental domains. Addressing these aspects could improve the registration of ADRs and may contribute to patient safety.
AB - Background: Systematically registering ADRs in electronic health records (EHRs) likely contribute to patient safety as it enables the exchange of drug safety data. Currently, ADRs registrations by healthcare professionals (HCPs) is suboptimal. This study aimed to identify barriers and facilitators perceived by HCPs to register ADRs systematically in EHRs. Research Design and Methods: A qualitative study with individual interviews was conducted among specialist physicians and hospital pharmacists from 10 different Dutch hospitals. A semi-structured interview guide was used to identify experienced barriers and facilitators for systematically registering ADRs. Data was analyzed following thematic analysis. Themes within barriers and facilitators were aligned with the Capability–Opportunity-Motivation–Behavior (COM-B) framework. Results: In total, 16 HCPs were interviewed. Identified barriers were: lack of knowledge to recognize ADRs, time constraints, inadequate IT system, lack of support, stuck in routine, and not recognizing the importance of registering ADRs. Identified facilitators were: enhanced knowledge and awareness of ADRs, functional IT systems, expanding accountability for registration, and motivation toward registering. Conclusions: Barriers and facilitators for registering spanned all aspects of the COM-B model and occurred in individual, social and environmental domains. Addressing these aspects could improve the registration of ADRs and may contribute to patient safety.
KW - Adverse drug reaction
KW - adverse drug reaction registration
KW - capability–opportunity - motivation–behavior (COM-B) model
KW - hospitals
UR - http://www.scopus.com/inward/record.url?scp=85123675439&partnerID=8YFLogxK
U2 - https://doi.org/10.1080/14740338.2022.2020756
DO - https://doi.org/10.1080/14740338.2022.2020756
M3 - Article
C2 - 35060443
SN - 1474-0338
VL - 21
SP - 699
EP - 706
JO - Expert opinion on drug safety
JF - Expert opinion on drug safety
IS - 5
ER -